The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus
- 130 Downloads
To investigate the effect of add-on exenatide to insulin on glycemic excursion and the counter-regulatory hormone in response to hypoglycemia in patients with type 1 diabetes mellitus (T1DM).
30 patients with T1DM were recruited and randomly assigned to exenatide + insulin-treated group (group 1, n = 15) or insulin-only-treated group (group 2, n = 15) for 4 weeks. All patients had continuous glucose monitor system (CGMS) applied at before (week-0) and after (week-4) treatment to evaluate the glycemic variability. All patients had an arginine-stimulated test at before and after treatment. Six patients from each group also had hypoglycemic clamp test to assess counter-regulatory hormone level.
Patients in the exenatide group had significant reductions in body weight, body mass index (BMI), total insulin dose, bolus insulin dose, fructosamine, and glycemic excursion after 4 weeks’ treatment. Compared with patients in group 2, the mean amplitude of glycemic excursion (MAGE) and coefficient of variation (CV) of exenatide group decreased significantly. Similarly, a significant decrease of glucagon (GLC) in the arginine-stimulated test was found in group 1. No significant changes of GLC, growth hormone (GH), cortisol (COR), epinephrine (E), and norepinephrine (NE) were found in both groups during hypoglycemia clamp test. However, patients who had residual islet function in group 1 showed an upward trend of basic C-peptide (C-P) and GLC during the hypoglycemia period.
Although exenatide could inhibit glucagon secretion during euglycemia or hyperglycemia in patients with T1DM, it has no effect on GLC and counter-regulatory hormones during hypoglycemia clamp in patients with no functional residual islet test.
KeywordsType 1 diabetes mellitus Exenatide Glycemic excursion
This study received financial support from the Science Association fund of Nanjing (201303005), JiangSu, China.
Compliance with ethical standards
Conflict of interest
The authors have no conflicts interest to declare.
The research study was approved by the ethics committee at Nanjing First Hospital, Nanjing, China.
Our research involved human participants who had obtained informed consent.
- 4.Wood JR, Miller KM, Maahs DM et al (2013) Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 36(7):2035–2037CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Pieber TR, Deller S, Korsatko S et al (2015) Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo- controlled, double-blind, crossover trial. Diabetes Obes Metab 17(8):742–750CrossRefPubMedGoogle Scholar
- 14.McGee P, Steffes M, Nowicki M et al (2014) Short report: pathophysiology Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot Study. Diabet Med 31:1264–1268CrossRefPubMedPubMedCentralGoogle Scholar